Publications by authors named "Dan V Spiegelman"
Background: The majority of experimental approaches for cancer immunotherapy are tested against relatively small tumors in tumor-bearing mice, because in most cases advanced cancers are resistant to the treatments. In this study, we asked if even late-stage mouse tumors can be eradicated by a rationally designed combined radio-immunotherapy (CRI) regimen.
Methods: CRI consisted of local radiotherapy, intratumoral IL-12, slow-release systemic IL-2 and anti- CTLA-4 antibody.
NB, being a highly metastatic cancer, is one of the leading causes of cancer-related deaths in children. Increased disease recurrence and clinical resistance in patients with metastatic high-risk NBs (HR-NBs) result in poor outcomes and lower overall survival. However, the paucity of appropriate in vivo models for HR-NB metastasis has limited investigations into the underlying biology of HR-NB metastasis.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of an in-situ vaccine using CpG oligodeoxynucleotide and OX40 agonist antibody in activating anti-tumor responses in mice, focusing on factors like tumor volume and model type.
- Results indicate that larger tumor volumes reduce the vaccine's anti-tumor effectiveness, with variations observed between different tumor types (B78 melanoma vs. A20 lymphoma).
- The addition of anti-CTLA-4 improved the vaccine's efficacy in the A20 model, suggesting that multiple preclinical conditions must be considered for effective cancer immunotherapy development.